Non-Hodgkin lymphoma often involves the liver. However, primary hepatic lymphoma (PHL) confined to the liver without evidence of lymphomatous involvement is rare. The optimal therapy for PHL is still unclear. Most patients present with poor prognostic features. Here, we report a case of PHL treated with liver resection followed by chemotherapy. A 65-year-old male was referred for further evaluation about a liver mass detected on ultrasound. Abdominal computed tomography (CT) scan showed well-defined single mass of 6 cm in diameter. Positron emission tomography/CT scan revealed a hot uptake lesion on the segment 8 of the liver. Colonoscopy showed no abnormal finding. It was diagnosed as intrahepatic cholangiocarcinoma. A right anterior sectionectomy was performed. Postoperative pathology revealed diffuse large B-cell lymphoma. Bone marrow biopsy showed normal findings. The final diagnosis was confirmed as PHL. The patient subsequently received six cycles of R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) regimen. The patient is doing well without relapse after 60 months of follow-up. Because of its rarity and the lack of specific laboratory, radiological, or clinical finding, liver biopsy is essential for definite diagnosis of PHL. Optimal treatment for PHL is currently uncertain. However, surgical resection followed by adjuvant chemotherapy should be considered for select individuals to achieve better outcome. (Ann Hepatobiliary Pancreat Surg 2017;21:163-167)
INTRODUCTION
Although non-Hodgkin's lymphoma (NHL) commonly involves the liver in more advanced stages, primary involvement of the liver in this disease is rare. 1 Primary hepatic lymphoma (PHL) is an extremely rare malignancy, representing ＜1% of all extranodal lymphomas. 2 Clinical manifestations, laboratory findings, and radiologic features of PHL are non-specific. Therefore, PHL might be misdiagnosed as primary hepatic tumor or metastatic hepatic tumor. 3 Although most patients are treated with chemotherapy, various approaches including surgery and radiotherapy have been attempted for better outcome.
The optimal treatment of PHL remains unclear and its prognosis is poor. 4 We report a case of PHL in a patient who had a mass-forming intrahepatic cholangiocarcinoma preoperatively. After surgical resection followed by chemotherapy, he has maintained long-term remission.
CASE
A 65-year-old man was transferred to our hospital for further evaluation of a liver mass that had been detected by ultrasound. shown that surgery followed by chemotherapy has a better outcome. 4 In addition, postoperative chemotherapy has better outcome. 4 Moreover, postoperative chemotherapy is found to be the only prognostic factor for survival. 4 In patients with localized disease, surgery followed by adjuvant chemotherapy should be considered to prevent dis-ease recurrence. 5 Similarly, a large review of the literature has shown that patients treated with surgery followed by chemotherapy have better survival rates. 9 The Whether systemic chemotherapy alone will give results comparable to surgery in resectable cases is currently unclear. The optimal treatment for PHL may continue to be elusive. 9 In conclusion, PHL is a rare disease. It is easy to misdiagnose it due to the lack of specific clinical manifestations, imaging findings, and biochemical indicators. been clarified yet. In select patients with localized tumor lesion, surgery followed by adjuvant chemotherapy should be considered for better outcome.
